Literature DB >> 23364151

Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas.

Stamatis Gregoriou1, Dimitris Rigopoulos, Christos Stamou, Vasiliki Nikolaou, George Kontochristopoulos.   

Abstract

BACKGROUND: Cutaneous xanthomas develop as a result of intracellular and dermal deposition of lipids in either hyper- or normolipidemic patients. Plane xanthomas may signal the presence of an underlying monoclonal gammopathy, chronic myelomonocytic leukemia, or cutaneous T-cell lymphoma. Investigators have suggested that xanthomatized T cells may result in induction of plane xanthomas.
METHODS: We report the case of a patient with mycosis fungoides (MF) and plane xanthomas who was treated with bexarotene for his MF.
RESULTS: Significant improvement in the clinical signs of MF was observed within 3 months. We also observed a substantial regression of the xanthomas after 5 months of treatment. Complete clinical remission of both the MF and xanthomas was obtained after 6 months. The patient was still free of xanthomas after 3 years of follow-up.
CONCLUSION: Bexarotene led to the clearing of the cutaneous lesions of cutaneous T-cell lymphoma and plane xanthomas. This may be due to an effect of bexarotene on the aberrant T cells that may cause xanthomatization.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23364151     DOI: 10.2310/7750.2012.12022

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  5 in total

Review 1.  Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.

Authors:  Yu Yamazaki; Meghan M Painter; Guojun Bu; Takahisa Kanekiyo
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

Review 2.  [Diffuse plane xanthomas associated with mycosis fungoides].

Authors:  Julia K Winkler; Jochen Hoffmann; Alexander Enk; Ferdinand Toberer
Journal:  Hautarzt       Date:  2019-06       Impact factor: 0.751

3.  Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.

Authors:  Masaya Tachibana; Mitsuru Shinohara; Yu Yamazaki; Chia-Chen Liu; Justin Rogers; Guojun Bu; Takahisa Kanekiyo
Journal:  Exp Neurol       Date:  2015-12-11       Impact factor: 5.330

Review 4.  Molecular Insight into the Therapeutic Promise of Targeting APOE4 for Alzheimer's Disease.

Authors:  Abdullah Al Mamun; Md Sahab Uddin; Md Fahim Bin Bashar; Sonia Zaman; Yesmin Begum; Israt Jahan Bulbul; Md Siddiqul Islam; Md Shahid Sarwar; Bijo Mathew; Md Shah Amran; Ghulam Md Ashraf; May N Bin-Jumah; Shaker A Mousa; Mohamed M Abdel-Daim
Journal:  Oxid Med Cell Longev       Date:  2020-05-15       Impact factor: 6.543

5.  Diffuse Normolipemic Plane Xanthoma (DNPX) of the Neck without Xanthelasma Palpebrum.

Authors:  Uwe Wollina; Jacqueline Schönlebe; Georgi Tchernev; Torello Lotti
Journal:  Open Access Maced J Med Sci       Date:  2018-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.